Lupin Introduces New PrEP Drug Equivalent to Truvada in the US

The pharmaceutical company, Lupin, announced the launch of its new Truvada equivalent drug in the United States. The announcement came at the close of the stock market on Friday, June 25th. The drugs, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets, 200 mg/300 mg, have been approved by the United States Food and Drugs Administration (FDA).

The two medications are the generic equivalent of Truvada Tablets 200 mg/300 mg, manufactured by Gilead Sciences, Inc. According to a news report, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets are indicated in combination with other antiretroviral agents for treating HIV-1 infection. The drugs also work for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually transmitted HIV-1 disease.

The Truvada equivalent drugs are already showing promise of possibly dominating the market. In March 2021, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets (RLD: Truvada) had an estimated market annual sale of USD 2.1 billion in the United States only. Before the announcement on Friday, Lupin’s shares rose 1.13% and settled at Rs 1,152.35.

Despite the emergence of these new drugs, Truvada continues to lead the PrEP drug market. Although considered expensive by many users, many people still see it as a likely option due to its effectiveness. However, as effective as the drug is, its manufacturers, Gilead Sciences, Inc., have faced several lawsuits from those who suffered permanent damage to their kidneys and bones.

Other more severe problems are liver damage, potentially fatal lactic acidosis, and immune reconstitution syndrome. The less severe side effects are headaches, nausea, rash, vomiting, and weight loss. Since the first batch of lawsuits commenced in May 2018, many more people have commenced actions to get compensation.

Find out more about Truvada lawsuits and your chances of success from our mass tort lawyers.